Scientific Journals
News and Features
AAPS Meetings and Education
  Products and Services
  AAPS Member Services
  AAPS Press Room
  Marketing Opportunities
  Affiliated Organizations
  Join AAPS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AAPS PRESSROOM: News Releases
   Member Directory  Marketplace  News  Annual Meeting  Career Center  Login  

FOR IMMEDIATE RELEASE

Contact:Debbie Werfel

December 15, 2000

703-248-4743

 

werfel@aaps.org

 

Jim Greif

 

703-248-4744

 

greifj@aaps.org

AAPS Workshop Addresses Pre-Approval Inspections by Regulatory Agencies

ARLINGTON, Va. — The American Association of Pharmaceutical Scientists (AAPS) will present the AAPS Workshop on Practical Approaches to Current Pre-Approval Inspection Initiatives: Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) on Jan. 8-10, 2001 in Arlington, Va. 

The workshop will provide scientists with an in-depth review of Pre-Approval Inspections conducted by FDA and other regulatory agencies and practical approaches from the industrial perspective.

“This workshop is designed to help people in the industry who have the responsibility of coordinating inspections by governing agencies. The workshop also addresses what to expect from European and Canadian agencies,” said Chris Bapatla, Ph.D., the workshop’s planning committee chairman.

Workshop attendees will:

  • Gain an understanding of what to expect during an audit;
  • Find out the most common observations made during inspections;
  • Learn how to prepare for successful Pre-Approval Inspection outcomes; and
  • Gain insight into agency and industrial experiences with pre-approval inspections.

Session topics include:

  • The FDA inspection process;
  • New drug application (NDA) pre-approval inspection program;
  • NDA and abbreviated new drug application (ANDA) review process;
  • Pre-approval inspection program with the active pharmaceutical ingredient manufacturer, generic, and excipient industry perspectives;
  • Most common observations made during GMP compliance audits of new drug applications and abbreviated new drug application dosage form manufacturers;
  • GMP inspections with industry and FDA updates; and
  • Unique requirements for biological active pharmaceutical ingredients and pre-approval inspections experiences.

For more information on this workshop, including a complete preliminary program, registration fees, and accommodations, visit AAPS Pharmaceutica at www.aapspharmaceutica.com/pai.

About AAPS

AAPS is a professional, scientific society of more than 11,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS aims to advance science through the open exchange of scientific knowledge, serve as an information resource, and contribute to human health through pharmaceutical research and development. For more information about AAPS, visit AAPS Pharmaceutica at www.aapspharmaceutica.com.

* * *



American Association of Pharmaceutical Scientists

2107 Wilson Blvd, Suite 700, Arlington, VA 22201-3046
Main Telephone: 703 243 2800 Main Fax: 703 243 9650
Email: aaps@aaps.org
View disclaimer
Please email your comments or questions regarding this web site to
webmaster@aaps.org